CrushSCI.com
187.2Average days
159Median days
47Fastest days
490Longest days
1642025 publications

Paper Review Records

All Paper Review Records

15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

47 days

First-in-human anti-Trop2 CAR-T cell therapy in refractory INI-1/BRM-deficient sinonasal carcinoma: A case report

Authors
Guangfei Li; Yuting Lai; Liang Wang; Hongjia Zhu; Min Chen; Jifang Wang; Taomin Huang; Liqing Kang; Nan Xu; Minghao Li; Xiaoyan Lou; Zhou Yu; Wei Wang; Minghao Fan; Jiali Wu; Haitao Wu; Lei Yu; Peijie He; Hongmeng Yu; Jian ChenShow moreShow less
Affiliations
ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China; School of Pharmacy, East China Normal University, Shanghai 200062, China; Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai 200000, China; Department of Nursing, Eye & ENT Hospital, Fudan University, Shanghai 200031, China; Department of Pharmacy, Eye & ENT Hospital, Fudan University, Shanghai 200031, China; Shanghai Key Laboratory of Gene Editing and Cell Therapy for Rare Diseases, Fudan University, Shanghai 200031, ChinaShow moreShow less
Source PDF DOI Publisher page
159 days

ICAM-1 as a biomarker of efficacy for oncolytic coxsackievirus A21 in patient-derived Ewing sarcoma models

Authors
Richard T. Baugh; Tyler Barr; Elizabeth A. Roundhill; Fay Ismail; Milene Volpato; Graham P. Cook; Susan A. Burchill; Fiona Errington-MaisShow moreShow less
Affiliations
Leeds Institute of Medical Research, University of Leeds, St James’s University Hospital, Wellcome Trust Brenner Building, Beckett Street, Leeds LS9 7TF, UKShow moreShow less
Source PDF DOI Publisher page
113 days

Phase 1 evaluation of APN401, an autologous CBL-B-silenced PBMC therapy, in advanced solid tumors

Authors
Alexander Dohnal; Nina Worel; Thomas Bogenrieder; Thorsten Fuereder; Martin Burian; Dominik Wolf; Gerald Prager; Richard Greil; Anja Peterbauer-Scherb; Beate Schrenk; Stefan Bunka; Ernesto Abila; Felix Batrina; Maria Urban; Julia Buchberger; Alice Schwarzboeck; Bernhard Peball; Sandra Seidl; Hannes Muehleisen; Stefan Stranner; Mario Kuttke; Angela Halfmann; Sarah Bischof; Andreas Birbach; Romana GugenbergerShow moreShow less
Affiliations
InvIOs GmbH, Campus Vienna Biocenter 5, 1030 Vienna, Austria; Medical University of Vienna, Department of Transfusion Medicine and Cell Therapy, Waehringer Guertel 18-20, 1090 Vienna, Austria; Medical University of Vienna, Department of Medicine I, Division of Oncology, Waehringer Guertel 18-20, 1090 Vienna, Austria; Ordensklinikum Linz GmbH, Barmherzige Schwestern, Seilerstaette 4, 4020 Linz, Austria; Medical University Innsbruck, Department of Internal Medicine V, Hematology and Oncology, Anichstrasse 35, 6020 Innsbruck, Austria; Salzburg Cancer Research Institute, Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Muellner Hauptstrasse 48, 5020 Salzburg, Austria; Austrian Red Cross, Blood Transfusion Service for Upper Austria, Krankenhaustrasse 7, 4010 Linz, AustriaShow moreShow less
Source PDF DOI Publisher page
373 days

A novel spliceosome inhibitor triggers anti-tumor CD4+ and CD8+ T cell responses in murine models of pediatric-relevant cancer

Authors
Mélanie Demeules; Boris Letribot; Lisa Giraldo; Congcong Li; Alexandre Maucuer; Birgit Geoerger; Mouad Alami; Sébastien ApcherShow moreShow less
Affiliations
Université Paris-Saclay, INSERM UMR1015, 114 Rue Edouard Vaillant, 94800 Villejuif, France; Université Paris-Saclay, Gustave Roussy, INSERM UMR1363, Biothérapies Innovantes, 114 Rue Edouard Vaillant, 94800 Villejuif, France; Université Paris Cité, INSERM U1342, Institut de Recherche Saint-Louis (IRSL), Paris, France; Université Paris-Saclay, CNRS, BioCIS, 91400 Orsay, France; SABNP, Université Evry, INSERM U1204, Université Paris-Saclay, 91025 Evry, France; Gustave Roussy Cancer Campus, Department of Pediatric and Adolescent Oncology, Université Paris-Saclay, 114 Rue Edouard Vaillant, 94800 Villejuif, FranceShow moreShow less
Source PDF DOI Publisher page
275 days

Interleukin-21 expressing oncolytic vaccinia virus elicits systemic anti-tumor immune response and synergizes with immunotherapies

Authors
Rong Zhang; Tingting Wang; Yu Wang; Chenggang Hong; Yun Qin; Kangchen Ye; Hu Zhao; Fang Hu; Jinlu Cai; Jin FuShow moreShow less
Affiliations
Hangzhou Converd Co. Ltd., Hangzhou, China; Department of General Surgery, Fuzong Clinical Medical College of Fujian Medical University, Fuzhou, ChinaShow moreShow less
Source PDF DOI Publisher page
109 days

USP15 regulates mitotic fidelity, metastatic potential, and chemotherapeutic response in ovarian cancer cells

Authors
Ayokunnumi Ogunsanya; Fatimah Alfaran; Omuya Noel Amadu; Achuth PadmanabhanShow moreShow less
Affiliations
Department of Biological Sciences, University of Maryland Baltimore County, Baltimore, MD, USA; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USAShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does Molecular Therapy Oncology take to review a manuscript?

As of 2026-11-13, CrushSCI has 15 complete review records for Molecular Therapy Oncology. The fastest paper went from submission to acceptance in 47 days (First-in-human anti-Trop2 CAR-T cell therapy in refractory INI-1/BRM-deficient sinonasal carcinoma: A case report, received 2026-08-27, accepted 2026-10-13); the slowest took 490 days. The average is 187.2 days and the median is 159 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.